ReviewFrontiers in oncology2026
The risk of radiation necrosis from combined radiotherapy and BRAF inhibitor in lung adenocarcinoma brain metastases: a comprehensive review and future perspectives.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The management of lung adenocarcinoma with brain metastases (BMs) is particularly challenging when BRAF-V600E mutations emerge as a resistance mechanism to EGFR tyrosine kinase inhibitors. While the combination of BRAF/MEK inhibitors (e.g., dabrafenib and trametinib) and radiotherapy (RT) is a pivotal therapeutic strategy, it significantly increases the risk of radiation necrosis (RN). This review summarizes the current understanding of the molecular mechanisms and risk factors underlying RN development in this specific patient population. We detail how BRAFi exacerbate RT-induced vascular injury, blood-brain barrier (BBB) disruption, and inflammatory responses, focusing on MAPK pathway modulation, VEGF signaling inhibition, and paradoxical pathway activation. Clinical correlations regarding treatment timing and regimen choice are discussed. Finally, we propose comprehensive strategies to mitigate RN risk, including optimized treatment sequencing, RT dose adjustments, advanced imaging for early detection, and novel approaches for vascular repair. This review underscores prospective studies and standardized guidelines are urgently needed to refine combination strategies and improve outcomes for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.